These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7533030)

  • 21. Use of novel urodynamic parameters, detrusor contraction duration and detrusor contraction index, in men with lower urinary tract symptoms.
    Turner CD; Kuznetsov D; Contreras BA; Gerber GS
    Tech Urol; 1998 Sep; 4(3):136-40. PubMed ID: 9800891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A double-blind placebo-controlled study evaluating the onset of action of doxazosin gastrointestinal therapeutic system in the treatment of benign prostatic hyperplasia.
    Roehrborn CG; Prajsner A; Kirby R; Andersen M; Quinn S; Mallen S
    Eur Urol; 2005 Sep; 48(3):445-52; discussion 452. PubMed ID: 15996811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Profile of doxazosin in patients with benign prostatic hyperplasia.
    Janknegt RA
    Scand J Urol Nephrol Suppl; 1995; 168():21-7. PubMed ID: 7541548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia.
    Martorana G; Giberti C; Di Silverio F; von Heland M; Rigatti P; Colombo R; Casadei G; Pacifico P
    Eur Urol; 1997; 32(1):47-53. PubMed ID: 9266231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ambulatory urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin.
    Gerber GS; Contreras BA; Rukstalis DB
    Tech Urol; 1997; 3(3):164-7. PubMed ID: 9422449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Doxazosin Study Groups.
    Janknegt RA; Chapple CR
    Eur Urol; 1993; 24(3):319-26. PubMed ID: 7505224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study.
    Christensen MM; Bendix Holme J; Rasmussen PC; Jacobsen F; Nielsen J; Nørgaard JP; Olesen S; Noer I; Wolf H; Husted SE
    Scand J Urol Nephrol; 1993; 27(1):39-44. PubMed ID: 7684157
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Doxazosin gastrointestinal therapeutic system versus tamsulosin for the treatment of benign prostatic hyperplasia: a study in Chinese patients.
    Xue Z; Zhang Y; Ding Q; He Z; Wang J; Xu K
    Int J Urol; 2007 Feb; 14(2):118-22. PubMed ID: 17302567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study.
    Gillenwater JY; Conn RL; Chrysant SG; Roy J; Gaffney M; Ice K; Dias N
    J Urol; 1995 Jul; 154(1):110-15. PubMed ID: 7539854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of doxazosin in men with benign prostatic hyperplasia: urodynamic assessment.
    Ozbey I; Aksoy Y; Polat O; Biçgi O; Demirel A; Okyar G
    Int Urol Nephrol; 1999; 31(4):471-9. PubMed ID: 10668942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized double-blind study assessing 4 versus 8 mg. doxazosin for benign prostatic hyperplasia.
    MacDiarmid SA; Emery RT; Ferguson SF; McGuirt-Franklin R; McIntyre WJ; Johnson DE
    J Urol; 1999 Nov; 162(5):1629-32. PubMed ID: 10524884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia.
    Prieto L; Romero J; López C; Ortiz M; Pacheco JJ
    Urol Int; 2008; 81(1):66-71. PubMed ID: 18645274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension.
    Chung BH; Hong SJ
    BJU Int; 2006 Jan; 97(1):90-5. PubMed ID: 16336335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Morning versus evening dosing with doxazosin in benign prostatic hyperplasia: pharmacokinetics, efficacy and safety.
    Kirby RS
    Int J Clin Pract; 1998 Mar; 52(2):75-7. PubMed ID: 9624784
    [No Abstract]   [Full Text] [Related]  

  • 35. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia.
    Yamanishi T; Yasuda K; Kamai T; Tsujii T; Sakakibara R; Uchiyama T; Yoshida K
    Int J Urol; 2004 Jul; 11(7):501-9. PubMed ID: 15242359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Analysis of doxazosin efficacy in the treatment of the benign prostatic enlargement].
    Aganović D; Aganović K; Prcić A
    Med Arh; 2004; 58(3):153-6. PubMed ID: 15484855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An observational urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin.
    Gerber GS; Kim JH; Contreras BA; Steinberg GD; Rukstalis DB
    Urology; 1996 Jun; 47(6):840-4. PubMed ID: 8677574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Doxazosin in the treatment of benign prostatic hypertrophy].
    Rollema HJ; Janknegt RA
    J Urol (Paris); 1993; 99(6):314-5. PubMed ID: 7516377
    [No Abstract]   [Full Text] [Related]  

  • 39. A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction.
    Chapple CR; Carter P; Christmas TJ; Kirby RS; Bryan J; Milroy EJ; Abrams P
    Br J Urol; 1994 Jul; 74(1):50-6. PubMed ID: 7519112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia.
    Elhilali MM; Ramsey EW; Barkin J; Casey RW; Boake RC; Beland G; Fradet Y; Trachtenberg J; Orovan WL; Schick E; Klotz LH
    Urology; 1996 Mar; 47(3):335-42. PubMed ID: 8633398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.